Medplus Health Services Limited

December 14, 2023

The Listing Department **BSE Limited** **Phiroze Jeejebhoy Towers,** **Dalal Street, Fort,** **Mumbai – 400001** **BSE Scrip Code: 543427**	**The Listing Department** **National Stock Exchange of India Limited** **Exchange Plaza, 5th Floor** **Plot No. C/1, G Block,** **Bandra - Kurla Complex** **Bandra (East), Mumbai – 400051** **NSE Symbol: MEDPLUS**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30, read with Clause 20 Para A of Part A of Schedule III, of SEBI Listing Regulations, we would like to inform that one of our Subsidiary Company has received orders from Drugs and Control Authority. The detailed disclosure with respect to the orders as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023 is enclosed herewith as per "Annexure A"

The aforesaid information is also being placed on the website of the Company at www.medplusindia.com

Kindly take the same on records.

For MedPlus Health Services Limited

MANOJ KUMAR SRIVASTAVA Digitally signed by MANOJ KUMAR SRIVASTAVA Date: 2023.12.14 18:39:08 +05'30'

Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS 7460

Encl. Annexure A

MEDPLUS HEALTH SERVICES LIMITED ★ HYDERABAD

040-6724 672
Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India
CIN No: L85110TG2006PLC051845 I **Website:** www.medplusindia.com I **Email:**medplus@medplusindia.com

<u>Annexure A</u>

Details required under the Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023

Sr. No.	Name(s) of the Authority	Nature and details of the action(s) taken, initiated or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed
1	Assistant Director, Drugs Control Administration, Bellary Distrcit , Karnataka	Suspension of drug license for 2 days (Dec 21, 2023 to Dec 22, 2023	Letter dated: December 12,2023 Received on: December 13,2023	Violation of various conditions of licences pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945

Financial Impact:
There is no Financial impact. The Company is taking corrective action in this regard.

MEDPLUS HEALTH SERVICES LIMITED
HYDERABAD